In the last decade, there have been over 5000 clinical trials and yet only 2 approved drugs in the gene therapy space. This underlines the challenges in pre-clinical development, clinical trials, regulatory approvals and commercialization. Each vertical has witnessed tremendous improvements to encourage biopharma to invest heavily in gene therapies to address unmet clinical needs.   In a panel discussion at the BIO CEO & Investor Conference, industry experts reflected on their experiences of navigating the commercialization and approval landscape for cell and gene therapies. Moderated by Luca Issi, Senior Biotech Research Analyst at RNC Capital Market, the session included